Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294707 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
A Phase 1 study, sponsored by Eidos Therapeutics, a BridgeBio company.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT03294707 is a Phase 1 study that has completed, run by Eidos Therapeutics, a BridgeBio company. The registered enrollment target is 56 participants.
The verdict
NCT03294707, a Phase 1 study, has completed, sponsored by Eidos Therapeutics, a BridgeBio company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
Interventions
- DRUG Placebo Oral Tablet
- DRUG AG10 oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2018-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03294707
The ClinicalTrials.gov registry entry for NCT03294707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eidos Therapeutics, a BridgeBio company, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03294707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03294707 about?
NCT03294707 is a clinical study titled "Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10". This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
What is the current status of trial NCT03294707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2017-09-11. Estimated completion is 2018-05-18.
What interventions are being tested in trial NCT03294707?
The interventions under investigation include: Placebo Oral Tablet (DRUG), AG10 oral tablet (DRUG).
Who is sponsoring clinical trial NCT03294707?
This trial is sponsored by Eidos Therapeutics, a BridgeBio company, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.